Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Carolyn Lane

Carolyn Lane

Manager, Research Laboratory

Cancer Center Division

Collaboration(15)

Setsuko Chambers
Michele Chu-Pilli
Brianna Denton
Fernanda Sanchez Borchardt
Mitzi Miranda

Page 1 of 3

Grants(5)

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active·2023·$0 / $270.2K·
External
clinical trials, cancer treatment, immunotherapy, chemotherapy, women's health
A Phase 1/2, Open Label, Dose-Escalation Study Of Oral ORIN1001 With And Without Chemotherapy In The Treatment Of Subjects With Solid Tumors
Active·2022·$0 / $245.9K·
External
oncology, clinical trial, chemotherapy, solid tumors, dose escalation
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL114 in Subjects with Non-Hodgkins Lymphoma
Active·2022·$0 / $236.5K·
External
pharmacokinetics, oncology, clinical trial, safety, dose escalation
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients with Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy
Active·2022·$0 / $185.5K·
External
cancer immunotherapy, metastatic breast cancer, immunotherapy combinations, hormone therapy resistance
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
2023·$0 / $188.6K·
External
lymphoma, cancer treatment, immunotherapy, clinical trial, drug combination